Sell AstraZeneca, says UBS, which upgrades European rivals including GSK

UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.UBS took its ratings on AstraZeneca AZN, -2.82% AZN, +0.35% to sell from buy, while it upgraded GSK GSK, -0.44% GSK, +1.16% to buy from sell. It also upped Novartis NOVN, +0.25% NVS, -0.14% and Sanofi SAN, +0.03% SNY, -0.51% to buy from neutral, and Novo Nordisk NOVO.B, -0.19% NVS, -0.14% to neutral from sell.Analysts led by Matthew Weston say sector valuation ...